Thursday, February 15, 2018 3:15:12 AM
While I haven't seen a big gain or massive buys in MGC this last week, I have heard that more companies are looking into the Australian sector. Canopy is locked into Auscann (which looks like a frightening partnership considering Auscanns ties to Tasmanik alkaloids) so I wouldn't envisage them taking a stake in another small cap. Aurora is with Cann Group but aphria is looking into options to reduce their American exposures considerig the federal laws there and problems it may cause with the TSX and so on. So this leads me to believe they might want more international exposure in the way of an Australian company. My intel points me towards a biotech like Zelda and they have been very strong and had good gains this last week or two but Zelda is also has links with Auscann so maybe it's a pipeline effect from canopy. (This is complicated I know)
But aphria may be looking into MGC also as a way to diversify into the cosmetics industry, they would have a party in the states with that especially with the CBD component, AND MGC already has deals in place with online retailers and a 40 million deal in Korea which is one of the beauty capitals of the world considering the amount they spend on products per capita.
I would think that there are more deals done between Northern America and Australia in the future which may lead to a nice increase in PPS from both the premium on the shares for a buyout and also from the hype created once it had that stronger backing and the confidence bigger companies bring to investors to put their money into one stock over another. Legitimacy might be a better word. HOWEVER I think the most significant and long lasting impact would be a change in legislation loostening the restraints even on medical access in Australia. By increasing patient count they can further expand current production facilities and would have consistent domestic demand on top of exports which would also more than likely call for larger production facilities.
All this makes for more revenue and greater profit margins and then we will see a $5 share price. My estimate is 2-3 years conservatively.
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM
Avant Technologies to Implement AI-Empowered, Zero Trust Architecture in Its Data Centers • AVAI • Apr 29, 2024 8:00 AM
Bantec Reports an Over 50 Percent Increase in Sales and Profits in Q1 2024 from Q1 2023 • BANT • Apr 25, 2024 10:00 AM